Adaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $25.00

Adaptive Biotechnologies (NASDAQ:ADPT) had its price objective upped by BTIG Research from $24.00 to $25.00 in a research report sent to investors on Thursday morning,Benzinga reports. BTIG Research currently has a buy rating on the stock.

Several other equities research analysts have also recently issued reports on ADPT. Guggenheim boosted their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday. TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, July 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Friday, July 17th. JPMorgan Chase & Co. decreased their price target on shares of Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating for the company in a research note on Wednesday, May 6th. Finally, Morgan Stanley boosted their price target on Adaptive Biotechnologies from $18.00 to $20.00 and gave the company an “equal weight” rating in a report on Thursday, July 9th. Five investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Adaptive Biotechnologies currently has a consensus rating of “Moderate Buy” and an average price target of $23.33.

Adaptive Biotechnologies Stock Down 6.7%

NASDAQ:ADPT opened at $22.57 on Thursday. The company has a market cap of $3.61 billion, a price-to-earnings ratio of -55.05 and a beta of 2.07. Adaptive Biotechnologies has a twelve month low of $9.96 and a twelve month high of $24.57. The company has a current ratio of 4.79, a quick ratio of 3.22 and a debt-to-equity ratio of 2.22. The stock has a fifty day simple moving average of $19.43 and a 200-day simple moving average of $16.66.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, July 28th. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.12). The company had revenue of $71.55 million during the quarter, compared to the consensus estimate of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The company’s revenue for the quarter was up 21.5% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.17) earnings per share. Analysts anticipate that Adaptive Biotechnologies will post -0.43 EPS for the current year.

Insider Buying and Selling at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total transaction of $10,778,636.00. Following the completion of the sale, the insider owned 812,058 shares in the company, valued at $17,775,949.62. This represents a 37.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sharon Benzeno sold 154,768 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $21.14, for a total value of $3,271,795.52. Following the sale, the insider owned 221,278 shares of the company’s stock, valued at approximately $4,677,816.92. This represents a 41.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,305,787 shares of company stock worth $27,828,563 over the last quarter. 5.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in ADPT. California State Teachers Retirement System lifted its stake in shares of Adaptive Biotechnologies by 1.0% during the 2nd quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after purchasing an additional 933 shares during the last quarter. PNC Financial Services Group Inc. grew its stake in Adaptive Biotechnologies by 6.8% in the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after purchasing an additional 941 shares during the last quarter. Captrust Financial Advisors raised its holdings in Adaptive Biotechnologies by 7.6% in the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after purchasing an additional 1,119 shares in the last quarter. Assetmark Inc. raised its holdings in Adaptive Biotechnologies by 46.4% in the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock worth $61,000 after purchasing an additional 1,401 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Adaptive Biotechnologies by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after buying an additional 1,532 shares during the last quarter. 99.17% of the stock is owned by institutional investors.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Adaptive raised its 2026 MRD revenue outlook to $268 million-$278 million and outlined plans to separate the MRD business. Management and analysts view the transaction as a potential way to create a focused, higher-growth “pure-play” company and unlock shareholder value. Adaptive outlines MRD separation plan while raising 2026 MRD revenue guidance
• Positive Sentiment: Second-quarter revenue was approximately $71.6 million, above the roughly $65.4 million consensus estimate and up 21.5% year over year. Zacks also reported an adjusted loss of $0.10 per share, narrower than the expected $0.13 loss and the $0.17 loss in the prior-year quarter. Adaptive Biotechnologies Reports Q2 Loss, Beats Revenue Estimates
• Positive Sentiment: Analysts raised their targets after the results: TD Cowen increased its target to $28 and maintained a Buy rating, while BTIG lifted its target to $25 and also retained a Buy rating. Analyst price-target coverage
• Neutral Sentiment: Zacks noted that ADPT’s 52-week-high performance reflects improving fundamentals, but investors must assess whether revenue growth, margins and the MRD separation can support additional appreciation. Adaptive Biotechnologies Hit a 52 Week High
• Negative Sentiment: Morgan Stanley raised its target only to $22 and kept an Equal Weight rating, implying limited upside at recent trading levels. The company remains unprofitable, and reported GAAP results included a larger-than-consensus quarterly loss, highlighting ongoing execution and profitability risks.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.